New advances in ovarian cancer.

摘要: Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy in United States, with approximately 15,000 deaths per year. Platinum/taxane doublets have long been considered standard treatment regimen for advanced-stage disease; however, recent studies sought to improve on outcome this therapy. Intraperitoneal (IP) chemotherapy has shown yield superior progression-free survival (PFS) and overall (OS); logistical problems toxicities limited more widespread adoption. Recent also suggested that a “dose-dense” schedule paclitaxel combination carboplatin may result improved outcomes, impact biological therapies first-line setting under active investigation. In recurrent disease, preliminary results suggest novel doublet regimens such as pegylated liposomal doxorubicin similar activity platinum/taxane while carrying reduced risk allergic reactions. Additionally, targeted therapy remains an area investigation, evidence agents PARP inhibitors, anti-angiogenics, PI3 kinase inhibitors. Here, we review advances our understanding its both newly diagnosed settings.